How to take and use Trabectedin correctly

The use of Trabectedin (Trabectedin) needs to be strictly carried out in professional medical institutions, because it is a prescription-grade anti-tumor drug and does not exist in oral preparations. The standard recommended protocol is a 24-hour continuous intravenous infusion through a central venous catheter every 21 days. The dose is calculated based on the patient's body surface area, generally 1.5 mg/square meter. This long-term, low-speed infusion method can ensure the stable concentration of the drug in the blood, reduce acute toxic reactions, and is also consistent with its pharmacokinetic characteristics.

In clinical operations, liver function is an important parameter in determining the dosage regimen. For patients with moderate hepatic impairment, the recommended dose should be lowered to 0.9 mg/m2 to avoid serious adverse reactions caused by drug accumulation in the body. If the patient's bilirubin exceeds three times the upper limit of normal, or liver enzyme levels are significantly elevated, it is not recommended to use trabectedin to avoid aggravating liver damage. Therefore, liver function, blood routine, and creatine phosphokinase levels need to be monitored regularly during treatment in order to detect adverse reactions early and adjust the plan.

Before administration, glucocorticoids are usually supplemented as pretreatment, which can not only reduce liver toxicity, but also relieve common side effects such as nausea and vomiting. Trabectedin can be used alone or in combination with other drugs. For example, in the treatment of ovarian cancer, it is often combined with drugs such as docetaxel to enhance the efficacy.

It needs to be emphasized that trabectedin should not be arbitrarily changed in dosage or shortened in the course of treatment. Excessive dosage may increase the risk of severe bone marrow suppression and liver damage, while insufficient dosage may affect the therapeutic effect. Patients must receive infusions on a regular basis under the guidance of an oncologist, and the infusions must be dynamically adjusted based on individual responses.

Overall, the standardized use of trabectedin represents the concept of "individualized dose management" in modern tumor treatment, which not only pursues the maximization of efficacy but also focuses on safety control. Its medication principles emphasize precise dosing, strict monitoring and physician leadership, which are important features that distinguish it from traditional chemotherapy.

Reference materials:https://www.drugs.com/monograph/trabectedin.html